Improving Representation in Coronary Stent PMA Studies: A Focus on Site Selection
Recent research highlights ongoing disparities in representation within clinical trials for coronary stents, particularly concerning minority groups, and women. While the efficacy of these devices is well-established, ensuring that trial results are generalizable to the broader patient population remains a critical challenge. A study published in the Journal of the American College of Cardiology suggests that targeted site selection could improve minority enrollment, but alternative strategies are needed to boost female participation.
The Challenge of Representation in Stent Trials
Percutaneous coronary intervention (PCI) with drug-eluting stents is a common treatment for coronary artery disease. However, clinical trials evaluating these devices often fail to reflect the demographic diversity of the patients who ultimately receive them. This underrepresentation raises concerns about whether the observed benefits of stents apply equally to all individuals.
Findings from the JACC Study
The study published in January 2026 in the Journal of the American College of Cardiology examined the alignment of coronary stent premarket approval (PMA) trial enrollment with the intended utilize population (IUP) in the United States. Researchers found that minority participants are markedly underrepresented, and women are modestly underrepresented in these trials.
The research indicates that minority enrollment is significantly influenced by the characteristics of the clinical trial sites. Strategically selecting sites with diverse patient populations could improve representation. However, the study emphasizes that improving female enrollment requires different approaches beyond simply targeting specific sites.
Alternative Strategies for Enhancing Female Enrollment
While targeted site selection may address minority underrepresentation, the study suggests that boosting female enrollment necessitates alternative strategies. The specific nature of these strategies was not detailed in the published research, but could include initiatives focused on addressing barriers to participation for women, such as childcare needs, transportation challenges, or concerns about trial procedures.
Broader Context: Ongoing Efforts to Improve Diversity in Clinical Trials
The issue of diversity in clinical trials extends beyond coronary stent studies. The American College of Cardiology (ACC) and the American Heart Association (AHA) have long recognized the importance of inclusive research and have issued guidelines to promote diversity in cardiovascular clinical trials. Since 1980, these organizations have worked to translate scientific evidence into clinical practice guidelines, with a growing emphasis on ensuring that research benefits all patients.
The PULSE Trial and Follow-Up Strategies
A separate trial, PULSE, investigated the impact of coronary computed tomography angiography (CCTA) versus ischemia-driven follow-up in patients undergoing PCI with second-generation drug-eluting stents. The PULSE trial, which enrolled 606 patients with a indicate age of 69 (18% female, 25% with diabetes), found that routine CCTA-based follow-up did not reduce the composite primary endpoint of all-cause death, spontaneous MI, unstable angina, or definite or probable stent thrombosis. Patients were followed for 18 months after randomization.
Key Takeaways
- Clinical trials for coronary stents often lack adequate representation of minority groups and women.
- Targeted site selection may improve minority enrollment in these trials.
- Enhancing female enrollment requires strategies beyond site selection.
- Ongoing efforts by organizations like the ACC and AHA aim to promote diversity in cardiovascular research.